AtriCure, Inc.

In the latest quarter, 6 analysts provided ratings for AtriCure (NASDAQ:ATRC), showcasing a mix of bullish and bearish perspectives. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 1 0 0 0 Last 30D 1 0 0 0 0 1M Ago 1 1 0 0 0 2M Ago 0 0 0 0 0 3M Ago 3 0 0 0 0 Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $44.0, along with a high estimate of $58.00 and a low estimate of $32.00. A 10.66% drop is evident in the current average compared to the previous average price target of $49.25. Deciphering Analyst Ratings: An In-Depth Analysis A comprehensive examination of how financial experts perceive AtriCure is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets. Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target Mike Matson Needham Lowers Buy $40.00 $46.00 Suraj Kalia Oppenheimer Announces Outperform $32.00 - Mike Matson Needham Maintains Buy $46.00 - Danielle Antalffy UBS Raises Buy $58.00 $57.00 Rick Wise Stifel Lowers Buy $42.00 $50.00 Mike Matson Needham Raises Buy $46.00 $44.00 Key Insights: Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AtriCure. This information offers a snapshot of how analysts perceive the ...Full story available on Benzinga.com

Related tickers: ATRC.

The headline numbers for AtriCure (ATRC) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Related tickers: ATRC.